Fauna Bio Company Market Research Report

Company Overview

Name: Fauna Bio

Mission: Fauna Bio is advancing human health through evolutionary insights by leveraging data from 100 million years of evolved disease resistance in mammals.

Founded by: No information is available.

Key People in the Company:

Ashley Zehnder: Co-founder and CEO

Katie Grabek: Co-founder and CSO

Linda Goodman: Co-founder and CTO

Jacqueline Galeas: Research Assistant

Rui Song: Senior Research Scientist

Ben Sajdak: Director of Emerging Animal Models

Bryan Burkey: Head, Therapeutics Discovery

Phil McNamara: Bioinformatics Platform Developer

Evelyn Tran: Senior Research Scientist

Poornima Neela: Research Operations Manager

Kacey Haptonstall: Translational Operations Manager

Ryan Sprenger: Senior Research Physiologist

Manashvi Borad: Data Engineer

Carlos Gonzalez-Lopez: Assistant Research Scientist

Gennady Gorin: Senior Scientist, Computational Biology

Natalie DeForest: Senior Scientist, Computational Genomics

Ashley Hermans: Research Assistant

Headquarters: 6460 Hollis St., Suite A, Emeryville, CA 94608

Number of Employees: No information is available.

Revenue: No information is available.

What the Company is Known For: Fauna Bio is recognized for its innovative AI-driven drug discovery leveraging genetic insights from extreme mammals to treat human diseases.

Products

Convergence™ AI Platform

Description: An artificial intelligence platform that utilizes proprietary biobank data to replicate disease resistance observed in extreme animal models for drug discovery.

Key Features:

Analyses data from mammalian hibernation biology and other extreme adaptations.

Identifies and enriches human druggable targets across a wide range of diseases.

Utilizes a custom Graph Neural Network with over 980 million model parameters.

Discovery and Therapeutics Programs

Description: Early discovery programs targeting a broad range of diseases such as neurodegeneration, heart failure, kidney disease, etc.

Key Features:

Partnered programs since 2023, including obesity-focused research.

Collaborates with academic institutions for data and experimental insights.

Recent Developments

New Collaborations and Partnerships

Eli Lilly Partnership (2023): Multi-year agreement to use Fauna’s Convergence™ AI platform for preclinical drug discovery in obesity with potential milestone payments up to $494 million.

Space-focused Research Programs

STASH Program: Novel microgravity laboratory for studying hibernation potential in space for human health applications, funded by a NASA Innovative Advanced Concepts grant.

ASCRIPTS Program: Investigates the protective effects of hibernation against radiation, funded by NASA and the Canadian Space Agency.

Academic Partnerships

UW Oshkosh Partnership: Collaboration to advance the study of 13-lined ground squirrels, seeking new treatment avenues for human diseases through extreme mammal adaptation.

Recognition and Achievements

Fauna Bio selected as part of the "Fierce 15" list of Best Biotechs in 2024.

Featured in the WSJ and Drug Discovery and Development for its pioneering work in using extreme mammal genetics for drug discovery.

Conclusion

Fauna Bio stands at the forefront of biotechnology, utilizing cutting-edge AI and genetic insights from extraordinary species to unlock novel drug targets, aiming to revolutionize human health treatment modalities.